Zydus Lifesciences has informed that it enclosed a copy of press release dated March 14, 2024 titled ‘Zydus receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials’.
The above information is a part of company’s filings submitted to BSE.